94 related articles for article (PubMed ID: 29112209)
1. Dual-target cancer theranostic for glutathione S-transferase and hypoxia-inducible factor-1α inhibition.
Li Z; Ding J; Chen C; Chang J; Huang B; Geng Z; Wang Z
Chem Commun (Camb); 2017 Nov; 53(92):12406-12409. PubMed ID: 29112209
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
3. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
4. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Kun Z; Yuling Y; Dongchun W; Bingbing X; Xiaoli L; Bin X
Technol Cancer Res Treat; 2016 Dec; 15(6):NP95-NP104. PubMed ID: 26647409
[TBL] [Abstract][Full Text] [Related]
6. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Tao NN; Zhou HZ; Tang H; Cai XF; Zhang WL; Ren JH; Zhou L; Chen X; Chen K; Li WY; Liu B; Yang QX; Cheng ST; Huang LX; Huang AL; Chen J
Oncotarget; 2016 Aug; 7(31):50117-50130. PubMed ID: 27367026
[TBL] [Abstract][Full Text] [Related]
7. HIF-1α-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia.
Liu XW; Su Y; Zhu H; Cao J; Ding WJ; Zhao YC; He QJ; Yang B
Pharmacol Res; 2010 Nov; 62(5):416-25. PubMed ID: 20637870
[TBL] [Abstract][Full Text] [Related]
8. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
9. Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
Liu Y; Gao F; Song W
Biomed Pharmacother; 2017 Apr; 88():342-348. PubMed ID: 28119236
[TBL] [Abstract][Full Text] [Related]
10. Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1α pre-mRNA in mice and in vitro.
Lee YM; Lim JH; Yoon H; Chun YS; Park JW
Hepatology; 2011 Jan; 53(1):171-80. PubMed ID: 21140472
[TBL] [Abstract][Full Text] [Related]
11. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound.
Sha HH; Wang Z; Dong SC; Hu TM; Liu SW; Zhang JY; Wu Y; Ma R; Wu JZ; Chen D; Feng JF
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29358310
[TBL] [Abstract][Full Text] [Related]
12. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.
Meng F; Nguyen XT; Cai X; Duan J; Matteucci M; Hart CP
Anticancer Drugs; 2007 Apr; 18(4):435-45. PubMed ID: 17351396
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
Lin D; Wu J
World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
[TBL] [Abstract][Full Text] [Related]
14. A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging.
Kong F; Liang Z; Luan D; Liu X; Xu K; Tang B
Anal Chem; 2016 Jun; 88(12):6450-6. PubMed ID: 27216623
[TBL] [Abstract][Full Text] [Related]
15. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
16. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
17. Sauchinone exerts anticancer effects by targeting AMPK signaling in hepatocellular carcinoma cells.
Kim YW; Jang EJ; Kim CH; Lee JH
Chem Biol Interact; 2017 Jan; 261():108-117. PubMed ID: 27871897
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y
J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
Peng X; Gao J; Yuan Y; Liu H; Lei W; Li S; Zhang J; Wang S
Bioconjug Chem; 2019 Nov; 30(11):2828-2843. PubMed ID: 31592652
[TBL] [Abstract][Full Text] [Related]
20. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
